Immunocore Expands IO Pact With Genentech To Target MAGE-A Antigens

19 Nov 2018

• By Sten Stovall

Genentech and Immunocore will now co-develop the biotech's therapeutic candidate IMC-C103C, an ImmTAC molecule targeting tumors that express melanoma-associated antigen A4.

Melanoma — MAGE-A antigens Are attractive targets for active specific and adoptive cancer immuno-therapies • Source: Shutterstock

Building on an existing multi-target R&D collaboration, Genentech Inc. and Immunocure will now co-develop the UK-based T-cell receptor specialist’s therapeutic candidate IMC-C103C, a proprietary molecule targeting tumors expressing the protein MAGE-A4 (melanoma-associated antigen A4), with first-in-human clinical trialing set for early next year.

Under the terms of the agreement, announced on Nov. 19, Immunocore will lead the clinical study to establish safety and...